Key result
Prostaglandin E1 reduced the overall risk of primary outcomes, including correlative reperfusion injury events and major adverse cardiac events, compared to control in patients undergoing reperfusion procedures.
Why the study?
Does intravenous prostaglandin E1 reduce correlative reperfusion injury events and major adverse cardiac events in patients with ischemia reperfusion injury undergoing PCI or cardiac surgery?
Meta-Analysis (n=445)
Does intravenous prostaglandin E1 reduce correlative reperfusion injury events and major adverse cardiac events in patients with ischemia reperfusion injury undergoing PCI or cardiac surgery?
Prostaglandin E1 pretreatment may reduce the incidence of correlative reperfusion injury events, major adverse cardiac events, and biomarker release in patients undergoing PCI or cardiac surgery.
Answers are grounded in this paper and cite their sources.
Supports PGE1 in reperfusion procedures to lower injury and MACE risk; confirms benefit across pooled trials.
BACKGROUND: Prostaglandin E1 (PGE1) is widely used as a pretreatment for myocardial reperfusion injury in animal experiments. However, the cardioprotective effects of PGE1 in patients have not been established. We performed a meta-analysis to investigate whether PGE1 is cardioprotective, based on the reduction of correlative reperfusion injury events (CRIE), major adverse cardiac events (MACE), and biomarker release in patients with ischemia reperfusion injury. METHODS: The Medline, EMBASE, and Cochrane databases were searched for randomized clinical trials confirming the effects of PGE1. Two investigators independently selected suitable trials, assessed trial quality, and extracted data. RESULTS: Six studies in patients undergoing percutaneous coronary intervention (4 studies) and cardiac surgery (2 studies), comprising a total of 445 patients, were included in this review. The results showed that PGE1 reduced the incidence of CRIE (relative ratio 0.4 [95% confidence interval 0.43, 0.95]), the incidence of MACE (0.35 [0.17, 0.70]), and the level of troponin T (standardized mean difference 20.28 [20.47, 20.09]), creatine kinase-MB (-1.74 [-3.21, - 0.27]), interleukin-6 (-1.37 [-2.69, - 0.04]), and interleukin-8 (-2.05 [-2.75, - 1.34]). CONCLUSION: PGE1 may have beneficial effects on myocardial reperfusion injury in the clinic.
No takes yet. Share an insight, caveat, or question.
Zhu et al. (2017) conducted a meta-analysis in Myocardial ischemia reperfusion injury (n=445). Prostaglandin E1 (PGE1) vs. Placebo or control was evaluated on Combined primary outcome (correlative reperfusion injury events and major adverse cardiac events) (RR 0.53, 95% CI 0.36-0.79). Prostaglandin E1 reduced the overall risk of primary outcomes, including correlative reperfusion injury events and major adverse cardiac events, compared to control in patients undergoing reperfusion procedures.
Synapse has enriched 10 related papers. Consider them for comparative context: